Streetbeat News

Price Targets

CMG

In the last 3 months, 31 analysts have provided 12-month price targets for Chipotle Mexican Grill (NYSE:CMG), with an average target of $2065.1, a high of $2400, and a low of $1743. The average price target has increased by 8.22% over the past month.

Portfolio Pulse from Benzinga Insights

June 14, 2023 | 1:00 pm

UPST

Mizuho analyst Dan Dolev reiterates an Underperform rating on Upstart Holdings (NASDAQ:UPST) and maintains a $16 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 1:00 pm

ACAD

Mizuho analyst Uy Ear reiterates a Neutral rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) and maintains a $20 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 12:59 pm

AXSM

Mizuho analyst Graig Suvannavejh reiterated a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a $95 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 12:58 pm

CFLT

Wells Fargo analyst Michael Turrin maintains an Overweight rating on Confluent (NASDAQ:CFLT) and raises the price target from $35 to $41.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2023 | 12:57 pm

UNH

Mizuho analyst Ann Hynes reiterates a Buy rating on UnitedHealth Group (NYSE:UNH) and maintains a $600 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 12:56 pm

AMD

Wells Fargo analyst Aaron Rakers maintains an Overweight rating on Advanced Micro Devices (NASDAQ:AMD) and raises the price target from $120 to $150.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2023 | 12:56 pm

AGR

Mizuho analyst Anthony Crowdell has reiterated a Neutral rating on Avangrid (NYSE:AGR) and maintained a $39 price target.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 12:55 pm

NXT

Mizuho analyst Anthony Crowdell maintains a Buy rating on NEXTracker (NASDAQ:NXT) and raises the price target from $40 to $45.

Portfolio Pulse from richadhand@benzinga.com

June 14, 2023 | 12:54 pm

BPMC

Wells Fargo analyst Derek Archila maintains an Equal-Weight rating on Blueprint Medicines (NASDAQ:BPMC) and raises the price target from $48 to $55.

Portfolio Pulse from Benzinga Newsdesk

June 14, 2023 | 12:54 pm